Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eliscer Guzman

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Circulation. Cardiovascular Quality and Outcomes|December 6, 2022
Peripheral Vascular Interventions in Office-Based Laboratories: Good News for Disparities or Profit Margins?Wayne B Batchelor, Eliscer Guzman, Carlos J Rodriguez
Current Medicinal Chemistry|July 16, 2021
Environmental Factors Modifying HDL FunctionalityConstantine E Kosmas, Andreas Sourlas, Eliscer Guzman, et al.
Patient Preference and Adherence|November 23, 2018
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemiaConstantine E Kosmas, Delia Silverio, Julio Ovalle, et al.
Annals of Translational Medicine|January 4, 2019
Role of spironolactone in the treatment of heart failure with preserved ejection fractionConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
World Journal of Cardiology|December 5, 2019
Novel lipid-modifying therapies addressing unmet needs in cardiovascular diseaseConstantine E Kosmas, Andreas Sourlas, Delia Silverio, et al.
Drugs in Context|December 6, 2018
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitusConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Drugs in Context|September 15, 2018
Primary genetic disorders affecting high density lipoprotein (HDL)Constantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Drugs in Context|December 7, 2017
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapyConstantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, et al.
Annals of Translational Medicine|September 27, 2019
Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effectsPeter D Montan, Andreas Sourlas, Jiohanna Olivero, et al.
Drugs in Context|November 19, 2021
New and emerging lipid-modifying drugs to lower LDL cholesterolConstantine E Kosmas, Dafni Pantou, Andreas Sourlas, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Circulation. Cardiovascular Quality and Outcomes|December 6, 2022
Peripheral Vascular Interventions in Office-Based Laboratories: Good News for Disparities or Profit Margins?Wayne B Batchelor, Eliscer Guzman, Carlos J Rodriguez
Current Medicinal Chemistry|July 16, 2021
Environmental Factors Modifying HDL FunctionalityConstantine E Kosmas, Andreas Sourlas, Eliscer Guzman, et al.
Patient Preference and Adherence|November 23, 2018
Patient adherence, compliance, and perspectives on evolocumab for the management of resistant hypercholesterolemiaConstantine E Kosmas, Delia Silverio, Julio Ovalle, et al.
Annals of Translational Medicine|January 4, 2019
Role of spironolactone in the treatment of heart failure with preserved ejection fractionConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
World Journal of Cardiology|December 5, 2019
Novel lipid-modifying therapies addressing unmet needs in cardiovascular diseaseConstantine E Kosmas, Andreas Sourlas, Delia Silverio, et al.
Drugs in Context|December 6, 2018
Impact of lipid-lowering therapy on glycemic control and the risk for new-onset diabetes mellitusConstantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Drugs in Context|September 15, 2018
Primary genetic disorders affecting high density lipoprotein (HDL)Constantine E Kosmas, Delia Silverio, Andreas Sourlas, et al.
Drugs in Context|December 7, 2017
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapyConstantine E Kosmas, Eddy DeJesus, Rosmery Morcelo, et al.
Annals of Translational Medicine|September 27, 2019
Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effectsPeter D Montan, Andreas Sourlas, Jiohanna Olivero, et al.
Drugs in Context|November 19, 2021
New and emerging lipid-modifying drugs to lower LDL cholesterolConstantine E Kosmas, Dafni Pantou, Andreas Sourlas, et al.
Pageof 3